alpha-1 antitrypsin deficiency

News

GSK kicks out of Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

Patients

Breathing through barriers: Lived experience, innovation, an...

When a disease runs in your family, you don’t learn about it from textbooks. You learn about it at funerals, in hospital beds, and emergency rooms.

News

Beam launches $500m financing on base-editing trial data

Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.

News

Wave Life Sciences president and CEO Paul Bolno

Wave surges on first RNA editing data in humans

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

News

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for

GSK kicks out of Wave's AATD programme

Breathing through barriers: Lived experience, innovation, an...

Beam launches $500m financing on base-editing trial data

Wave surges on first RNA editing data in humans

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

FDA knocks back AstraZeneca's self-injected lupus drug

How to meet your physicians where they are online

alpha-1 antitrypsin deficiency

Editor's Picks